Marshall Wace’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Marshall Wace’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Buy	591,473 +198,830	+51%	+$794K	﹤0.01%	1650
2026 Q1	$919K	Buy	392,643 +144,855	+58%	+$374K	﹤0.01%	2178
2025 Q4	$335K	Buy	+247,788	New	+$361K	﹤0.01%	2409
2025 Q1	–	Sell	-89,012	Closed	-$270K	–	3163
2024 Q4	$270K	Hold	89,012	–	–	﹤0.01%	2268
2024 Q3	$328K	Hold	89,012	–	–	﹤0.01%	2097
2024 Q2	$364K	Hold	89,012	–	–	﹤0.01%	2083
2024 Q1	$1.4M	Hold	89,012	–	–	﹤0.01%	1519
2023 Q4	$1.35M	Sell	89,012 -181,826	-67%	-$2.65M	﹤0.01%	1371
2023 Q3	$5.43M	Sell	270,838 -245,207	-48%	-$6.22M	0.01%	843
2023 Q2	$14.6M	Buy	+516,045	New	+$12.4M	0.03%	596

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Marshall Wace's ZNTL Position: Q2 2026 in Review

Marshall Wace increased its Zentalis Pharmaceuticals (ZNTL) stake by 51% in Q2 2026, buying an estimated $794K and bringing the position to 591,473 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1650.

Marshall Wace first reported a position in ZNTL in Q2 2023 and has held it in 10 quarters since. The position peaked at $14.6M in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Marshall Wace held 591,473 shares of Zentalis Pharmaceuticals worth $2.87M as of Q2 2026.
Marshall Wace bought 198,830 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $794K.
Zentalis Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1650 holding.
Marshall Wace first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
Marshall Wace's Zentalis Pharmaceuticals position peaked at $14.6M in Q2 2023.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.